Our observation of VEGF-A and
VEGF-C expression by bone marrow–derived mps in the inflamed corneal stroma
10 indicate that they are a likely source of these factors during inflammation, when they may function to induce blood and lymphatic vessel formation.
50 Therefore, we felt it was relevant to try to determine whether NM
2-treated mps were functionally distinct from GSH-OE–treated mps, which would have an elevated icGSH. NM
2-treated mps exhibited significantly reduced expression of
VEGFR3, NRP-2, VEGFR-1, and podoplanin compared with GSH-OE–treated mps. Further, the NM
2-treated mps expressed elevated VEGF-A and reduced TNF-α levels in comparison with GSH-OEt–treated mps. We speculate that mps under oxidative conditions (such as induced by IL-4)
13,19–21 or reductive conditions (such induced by IFN-γ)
13,14,16,19–21 stimulate lymphatic or blood vessel growth by producing angiogenic, lymphangiogenic, or antiangiogenic factors. To date there has been no functional categorization of mps in terms of their effect on lymphangiogenesis. One report
51 suggests that IFN-γ–activated mps are not angiogenic, whereas IL-4–stimulated mps secrete proangiogenic factors. Despite the elevated secretion of VEGF-A, NM
2-treated mps might not have been affected because of their reduced expression of
VEGFR-1. Detailed study will be needed to clarify the contrasting effect of NM
2, namely the upregulation of VEGF-A and the downregulation of
VEGFR-1.